Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms

The requested reference [e375d7b6fff951315d44067ec2098953843c1076] no longer exists in our database. It has been replaced by the current reference: [457cfc1e6bc4d920a1a59ead4ce5f73cb4432476]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with Peptide Receptor Radionuclide Therapy (PRRT) (ethanol-stabilized Lu-177 dotatate).
Epistemonikos ID: c2e391127542f542d2fbd1f709650ad24b735146
First added on: Sep 26, 2026